New Tools to Improve Access to Medicare Part D Financial Assistance
June 15, 2023
For many low-income Medicare beneficiaries, the Part D Low-Income Subsidy (LIS) program (also called “Extra Help”) can be a lifeline,
Celebrating 35 years of making Medicare more accessible, affordable, and equitable!
Prescription Drugs
The Inflation Reduction Act (IRA) takes important steps to reduce drug prices and lower costs for people with Medicare and the program, such as capping beneficiary out-of-pocket spending; requiring Medicare to negotiate drug prices; and expanding eligibility for the full Part D low-income subsidy (LIS). We support an implementation process that centers the beneficiary experience and look forward to building upon these landmark policies.
Merck Sues in Longshot Bid to Derail Medicare Drug Price Negotiation
June 8, 2023
This week, the pharmaceutical giant Merck sued the U.S. Department of Health and Human Services (HHS), challenging Medicare’s authority to
Study Finds Older Adults Skipping Medications Due to Cost
May 25, 2023
A recently released study found that in 2022, over 20% of adults 65 and older experienced cost-related medication nonadherence, meaning
Final Rule Makes Important Changes to Medicare Advantage and Part D
April 13, 2023
This week, the Centers for Medicare & Medicaid Services (CMS) finalized proposed policy changes to Medicare Advantage (MA) and Part
The Medicare Drug Price Negotiation Program
April 13, 2023
Callers to our national helpline regularly report struggling to afford the prescription medications they need to maintain their health and well-being. The Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program could offer much-needed relief. In our comments, we offer recommendations to implement this program in a way that enhances affordability, ensures accuracy, and maximizes transparency.
People with Medicare Could Soon See More Inflation Reduction Act Drug Pricing Relief
March 16, 2023
Implementation of the drug pricing provisions of the Inflation Reduction Act (IRA) is underway. This week, Medicare Rights submitted comments
Part D Medicare Prescription Drug Inflation Rebate Program
March 11, 2023
The Inflation Reduction Act’s (IRA) Rebate Program will require drug companies to pay a rebate if they raise certain Part D drug prices faster than inflation, reining in the industry practice of sky-high annual price adjustments. This deterrent will strengthen beneficiary and program finances.
Part B Medicare Prescription Drug Inflation Rebate Program
March 11, 2023
The Inflation Reduction Act’s (IRA) Rebate Program will require drug companies to pay a rebate if they raise certain Part B drug prices faster than inflation, reining in the industry practice of sky-high annual price adjustments. This deterrent will strengthen beneficiary and program finances.
President’s Budget Outlines Policy and Spending Priorities
March 9, 2023
Today, the White House released President Biden’s budget request for fiscal year (FY) 2024, which begins on October 1. Though
Improving the Effectiveness of Extra Help for Prescription Drugs
March 1, 2023
Medicare’s Low-Income Subsidy (LIS) program (also called “Extra Help”) can be a lifeline, helping low- and moderate-income beneficiaries pay for coverage they would not otherwise be able to afford. But aspects of the program are woefully outdated, making it difficult for low- and moderate-income beneficiaries to access the help they need.
New Tools to Improve Access to Medicare Part D Financial Assistance
June 15, 2023
For many low-income Medicare beneficiaries, the Part D Low-Income Subsidy (LIS) program (also called “Extra Help”) can be a lifeline,
Merck Sues in Longshot Bid to Derail Medicare Drug Price Negotiation
June 8, 2023
This week, the pharmaceutical giant Merck sued the U.S. Department of Health and Human Services (HHS), challenging Medicare’s authority to
Study Finds Older Adults Skipping Medications Due to Cost
May 25, 2023
A recently released study found that in 2022, over 20% of adults 65 and older experienced cost-related medication nonadherence, meaning
Final Rule Makes Important Changes to Medicare Advantage and Part D
April 13, 2023
This week, the Centers for Medicare & Medicaid Services (CMS) finalized proposed policy changes to Medicare Advantage (MA) and Part
The Medicare Drug Price Negotiation Program
April 13, 2023
Callers to our national helpline regularly report struggling to afford the prescription medications they need to maintain their health and well-being. The Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program could offer much-needed relief. In our comments, we offer recommendations to implement this program in a way that enhances affordability, ensures accuracy, and maximizes transparency.
People with Medicare Could Soon See More Inflation Reduction Act Drug Pricing Relief
March 16, 2023
Implementation of the drug pricing provisions of the Inflation Reduction Act (IRA) is underway. This week, Medicare Rights submitted comments
Part D Medicare Prescription Drug Inflation Rebate Program
March 11, 2023
The Inflation Reduction Act’s (IRA) Rebate Program will require drug companies to pay a rebate if they raise certain Part D drug prices faster than inflation, reining in the industry practice of sky-high annual price adjustments. This deterrent will strengthen beneficiary and program finances.
Part B Medicare Prescription Drug Inflation Rebate Program
March 11, 2023
The Inflation Reduction Act’s (IRA) Rebate Program will require drug companies to pay a rebate if they raise certain Part B drug prices faster than inflation, reining in the industry practice of sky-high annual price adjustments. This deterrent will strengthen beneficiary and program finances.
President’s Budget Outlines Policy and Spending Priorities
March 9, 2023
Today, the White House released President Biden’s budget request for fiscal year (FY) 2024, which begins on October 1. Though
Improving the Effectiveness of Extra Help for Prescription Drugs
March 1, 2023
Medicare’s Low-Income Subsidy (LIS) program (also called “Extra Help”) can be a lifeline, helping low- and moderate-income beneficiaries pay for coverage they would not otherwise be able to afford. But aspects of the program are woefully outdated, making it difficult for low- and moderate-income beneficiaries to access the help they need.